Opioid-Induced Constipation Industry Research Report 2025

Summary

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

According to APO Research, the global Opioid-Induced Constipation market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Opioid-Induced Constipation is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Opioid-Induced Constipation is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Opioid-Induced Constipation is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Opioid-Induced Constipation include Takeda Pharmaceuticals, Bayer, Sanofi, Mallinckrodt, Salix (Bausch Health), AstraZeneca, Progenics Pharmaceuticals, Purdue Pharm and Nektar Therapeutics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Opioid-Induced Constipation, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Opioid-Induced Constipation.

The report will help the Opioid-Induced Constipation manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Opioid-Induced Constipation market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Opioid-Induced Constipation market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Opioid-Induced Constipation Segment by Company

Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
Opioid-Induced Constipation Segment by Type

Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others
Opioid-Induced Constipation Segment by Application

Hospital
Pharmacy
Other
Opioid-Induced Constipation Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid-Induced Constipation market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Opioid-Induced Constipation and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid-Induced Constipation.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Opioid-Induced Constipation manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Opioid-Induced Constipation by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Opioid-Induced Constipation in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Opioid-Induced Constipation Market Size (2020-2031)
2.2.2 Global Opioid-Induced Constipation Sales (2020-2031)
2.2.3 Global Opioid-Induced Constipation Market Average Price (2020-2031)
2.3 Opioid-Induced Constipation by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Methylnaltrexone Bromide
2.3.3 Lubiprostone
2.3.4 Naloxegol
2.3.5 Others
2.4 Opioid-Induced Constipation by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Hospital
2.4.3 Pharmacy
2.4.4 Other
3 Market Competitive Landscape by Manufacturers
3.1 Global Opioid-Induced Constipation Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Opioid-Induced Constipation Sales (K Units) of Manufacturers (2020-2025)
3.3 Global Opioid-Induced Constipation Revenue of Manufacturers (2020-2025)
3.4 Global Opioid-Induced Constipation Average Price by Manufacturers (2020-2025)
3.5 Global Opioid-Induced Constipation Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Opioid-Induced Constipation, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Opioid-Induced Constipation, Product Type & Application
3.8 Global Manufacturers of Opioid-Induced Constipation, Established Date
3.9 Global Opioid-Induced Constipation Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Takeda Pharmaceuticals
4.1.1 Takeda Pharmaceuticals Company Information
4.1.2 Takeda Pharmaceuticals Business Overview
4.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolio
4.1.5 Takeda Pharmaceuticals Recent Developments
4.2 Bayer
4.2.1 Bayer Company Information
4.2.2 Bayer Business Overview
4.2.3 Bayer Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Bayer Opioid-Induced Constipation Product Portfolio
4.2.5 Bayer Recent Developments
4.3 Sanofi
4.3.1 Sanofi Company Information
4.3.2 Sanofi Business Overview
4.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Sanofi Opioid-Induced Constipation Product Portfolio
4.3.5 Sanofi Recent Developments
4.4 Mallinckrodt
4.4.1 Mallinckrodt Company Information
4.4.2 Mallinckrodt Business Overview
4.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Mallinckrodt Opioid-Induced Constipation Product Portfolio
4.4.5 Mallinckrodt Recent Developments
4.5 Salix (Bausch Health)
4.5.1 Salix (Bausch Health) Company Information
4.5.2 Salix (Bausch Health) Business Overview
4.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Salix (Bausch Health) Opioid-Induced Constipation Product Portfolio
4.5.5 Salix (Bausch Health) Recent Developments
4.6 AstraZeneca
4.6.1 AstraZeneca Company Information
4.6.2 AstraZeneca Business Overview
4.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
4.6.4 AstraZeneca Opioid-Induced Constipation Product Portfolio
4.6.5 AstraZeneca Recent Developments
4.7 Progenics Pharmaceuticals
4.7.1 Progenics Pharmaceuticals Company Information
4.7.2 Progenics Pharmaceuticals Business Overview
4.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolio
4.7.5 Progenics Pharmaceuticals Recent Developments
4.8 Purdue Pharm
4.8.1 Purdue Pharm Company Information
4.8.2 Purdue Pharm Business Overview
4.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Purdue Pharm Opioid-Induced Constipation Product Portfolio
4.8.5 Purdue Pharm Recent Developments
4.9 Nektar Therapeutics
4.9.1 Nektar Therapeutics Company Information
4.9.2 Nektar Therapeutics Business Overview
4.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Nektar Therapeutics Opioid-Induced Constipation Product Portfolio
4.9.5 Nektar Therapeutics Recent Developments
4.10 Daiichi Sankyo
4.10.1 Daiichi Sankyo Company Information
4.10.2 Daiichi Sankyo Business Overview
4.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Daiichi Sankyo Opioid-Induced Constipation Product Portfolio
4.10.5 Daiichi Sankyo Recent Developments
4.11 Prestige
4.11.1 Prestige Company Information
4.11.2 Prestige Business Overview
4.11.3 Prestige Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Prestige Opioid-Induced Constipation Product Portfolio
4.11.5 Prestige Recent Developments
4.12 GSK
4.12.1 GSK Company Information
4.12.2 GSK Business Overview
4.12.3 GSK Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
4.12.4 GSK Opioid-Induced Constipation Product Portfolio
4.12.5 GSK Recent Developments
4.13 Shionogi
4.13.1 Shionogi Company Information
4.13.2 Shionogi Business Overview
4.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
4.13.4 Shionogi Opioid-Induced Constipation Product Portfolio
4.13.5 Shionogi Recent Developments
5 Global Opioid-Induced Constipation Market Scenario by Region
5.1 Global Opioid-Induced Constipation Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Opioid-Induced Constipation Sales by Region: 2020-2031
5.2.1 Global Opioid-Induced Constipation Sales by Region: 2020-2025
5.2.2 Global Opioid-Induced Constipation Sales by Region: 2026-2031
5.3 Global Opioid-Induced Constipation Revenue by Region: 2020-2031
5.3.1 Global Opioid-Induced Constipation Revenue by Region: 2020-2025
5.3.2 Global Opioid-Induced Constipation Revenue by Region: 2026-2031
5.4 North America Opioid-Induced Constipation Market Facts & Figures by Country
5.4.1 North America Opioid-Induced Constipation Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Opioid-Induced Constipation Sales by Country (2020-2031)
5.4.3 North America Opioid-Induced Constipation Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.4.6 Mexico
5.5 Europe Opioid-Induced Constipation Market Facts & Figures by Country
5.5.1 Europe Opioid-Induced Constipation Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Opioid-Induced Constipation Sales by Country (2020-2031)
5.5.3 Europe Opioid-Induced Constipation Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.5.9 Spain
5.5.10 Netherlands
5.5.11 Switzerland
5.5.12 Sweden
5.5.13 Poland
5.6 Asia Pacific Opioid-Induced Constipation Market Facts & Figures by Country
5.6.1 Asia Pacific Opioid-Induced Constipation Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Opioid-Induced Constipation Sales by Country (2020-2031)
5.6.3 Asia Pacific Opioid-Induced Constipation Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 Taiwan
5.6.10 Southeast Asia
5.7 South America Opioid-Induced Constipation Market Facts & Figures by Country
5.7.1 South America Opioid-Induced Constipation Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Opioid-Induced Constipation Sales by Country (2020-2031)
5.7.3 South America Opioid-Induced Constipation Revenue by Country (2020-2031)
5.7.4 Brazil
5.7.5 Argentina
5.7.6 Chile
5.8 Middle East and Africa Opioid-Induced Constipation Market Facts & Figures by Country
5.8.1 Middle East and Africa Opioid-Induced Constipation Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Opioid-Induced Constipation Sales by Country (2020-2031)
5.8.3 Middle East and Africa Opioid-Induced Constipation Revenue by Country (2020-2031)
5.8.4 Egypt
5.8.5 South Africa
5.8.6 Israel
5.8.7 Türkiye
5.8.8 GCC Countries
6 Segment by Type
6.1 Global Opioid-Induced Constipation Sales by Type (2020-2031)
6.1.1 Global Opioid-Induced Constipation Sales by Type (2020-2031) & (K Units)
6.1.2 Global Opioid-Induced Constipation Sales Market Share by Type (2020-2031)
6.2 Global Opioid-Induced Constipation Revenue by Type (2020-2031)
6.2.1 Global Opioid-Induced Constipation Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Opioid-Induced Constipation Revenue Market Share by Type (2020-2031)
6.3 Global Opioid-Induced Constipation Price by Type (2020-2031)
7 Segment by Application
7.1 Global Opioid-Induced Constipation Sales by Application (2020-2031)
7.1.1 Global Opioid-Induced Constipation Sales by Application (2020-2031) & (K Units)
7.1.2 Global Opioid-Induced Constipation Sales Market Share by Application (2020-2031)
7.2 Global Opioid-Induced Constipation Revenue by Application (2020-2031)
7.2.1 Global Opioid-Induced Constipation Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Opioid-Induced Constipation Revenue Market Share by Application (2020-2031)
7.3 Global Opioid-Induced Constipation Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Opioid-Induced Constipation Value Chain Analysis
8.1.1 Opioid-Induced Constipation Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Opioid-Induced Constipation Production Mode & Process
8.2 Opioid-Induced Constipation Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Opioid-Induced Constipation Distributors
8.2.3 Opioid-Induced Constipation Customers
9 Global Opioid-Induced Constipation Analyzing Market Dynamics
9.1 Opioid-Induced Constipation Industry Trends
9.2 Opioid-Induced Constipation Industry Drivers
9.3 Opioid-Induced Constipation Industry Opportunities and Challenges
9.4 Opioid-Induced Constipation Industry Restraints
10 Report Conclusion
11 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings